Erasca, Inc. 10-Q Summary
Business context and reporting period
Erasca is a clinical-stage precision oncology company developing therapies for RAS/MAPK pathway-driven cancers. Its pipeline includes naporafenib, ERAS-007, ERAS-601, ERAS-801 and discovery-stage programs. The filing covers the quarter and six months ended June 30, 2023, and was filed August 10, 2023.
The company has no approved products and has generated no product revenue. Management expects product revenue, if any, to remain several years away and may never occur.
Financial performance and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $26.2 million | $53.8 million |
| General and administrative expense | $9.8 million | $19.2 million |
| Total operating expenses | $36.0 million | $73.0 million |
| Interest income | $4.3 million | $8.1 million |
| Net loss | $31.8 million | $65.0 million |
| Net loss per share | $0.21 | $0.43 |
| Net cash used in operating activities | Not separately provided | $52.3 million |
At June 30, 2023, cash and cash equivalents were $138.8 million, short-term marketable securities were $178.5 million and long-term marketable securities were $48.1 million, for total cash, cash equivalents and marketable securities of approximately $365.3 million. The company had an accumulated deficit of $546.0 million and total stockholders’ equity of $362.7 million.
The company had no debt reported. Operating lease liabilities totaled $57.6 million, including $3.7 million classified as current. Future operating lease payments totaled $84.8 million, before $27.2 million of interest.
Six-month investing cash outflows were $94.0 million, principally reflecting $199.5 million of marketable-security purchases, $127.0 million of maturities, $20.0 million of in-process research and development payments, and $1.5 million of property and equipment purchases. Financing cash inflows were $0.8 million from stock-option exercises and the employee stock purchase plan.
Material changes versus the prior comparable period
- Second-quarter research and development expense decreased $1.3 million, or approximately 5%, to $26.2 million, primarily due to lower clinical, preclinical and discovery costs and lower outsourced services, partly offset by higher facilities, depreciation, stock-based compensation and personnel costs.
- Six-month research and development expense decreased $1.1 million to $53.8 million. The 2022 period included a $2.0 million Katmai development milestone recorded as in-process research and development; no such expense was recorded in 2023.
- General and administrative expense increased $1.3 million in the quarter and $3.7 million year to date, driven primarily by higher stock-based compensation and personnel costs.
- Net loss improved by $3.8 million in the quarter and $7.1 million year to date, largely because higher interest income offset operating expenses.
- Interest income increased to $4.3 million for the quarter and $8.1 million year to date, compared with $0.4 million and $0.5 million, respectively, in the prior periods.
- Common shares outstanding increased to approximately 150.4 million at June 30, 2023 from approximately 149.3 million at December 31, 2022. Stock options outstanding increased to 25.5 million from 17.4 million at year-end.
Guidance, outlook, commentary and risks
- Management believes available cash, cash equivalents and marketable securities will fund operations into the second half of 2025, based on current plans. The filing cautions that actual cash usage could differ materially.
- Naporafenib development is planned to include a Phase 1b trial in the second half of 2023 and a pivotal Phase 3 trial in NRAS-mutated melanoma in the first half of 2024. A Phase 1b dose-expansion readout for ERAS-007 plus encorafenib and cetuximab is expected between the second half of 2023 and the first half of 2024.
- The company expects a Phase 1b combination data readout for ERAS-601 plus cetuximab in the first half of 2024.
- Management expects operating expenses and losses to increase substantially as clinical development, manufacturing, personnel, intellectual-property and public-company activities expand.
- In June 2023, the company deprioritized several programs or combinations after clinical data, including ERAS-007 combinations with osimertinib, palbociclib and ERAS-601, and gated enrollment in one HERKULES-3 population. It also deprioritized ERAS-3490 and does not plan to actively enroll the AURORAS-1 trial.
- ERAS-801 received FDA Fast Track Designation in May 2023 and Orphan Drug Designation in June 2023.
- The company relies on third parties for manufacturing, clinical research, packaging, distribution and supply of combination therapies. Clinical, regulatory, manufacturing, financing, intellectual-property and market-acceptance risks remain material.
- The company has an at-the-market facility permitting up to $200 million of common-stock sales, but no shares had been sold under the facility through June 30, 2023. Future equity financing could dilute existing stockholders.
- On August 7, 2023, the company notified the Regents of the University of California that it would terminate the UCSF license agreement effective October 6, 2023, following deprioritization of the related S-IIG research program.
- The company reported no material legal proceedings, no material changes to previously disclosed risk factors, and effective disclosure controls as of June 30, 2023.
Important facts for investors to verify
- Verify the projected cash runway into the second half of 2025 against clinical-trial spending, milestone obligations and potential financing needs.
- Track initiation, enrollment, safety, efficacy and timing for the planned naporafenib Phase 1b and Phase 3 programs.
- Assess the impact of deprioritized programs and combinations on pipeline breadth, future research spending and strategic focus.
- Review the potential regulatory, development and sales milestones and royalty obligations under the Novartis and other license agreements.
- Monitor operating lease commitments, third-party manufacturing dependence and supply-chain redundancy.
- Evaluate dilution risk from 25.5 million outstanding options, 15.0 million shares available for future awards, the $200 million ATM facility and any future equity offerings.
- Confirm the effective termination of the UCSF license and any resulting effect on intellectual-property rights or development plans.